The majority of TILs in cancer are of the T-cell phenotype, which includes CD4+ (helper cells) and CD8+ (cytotoxic cells) lymphocytes, and it has been consistently shown that the presence of CD8+ T-lymphocytes in ER and HER2+ breast cancer are correlated with better clinical outcomes (Ali et al., 2014). Here, ERBB2 is linked to breast carcinoma.